Search

TRADEMARK BOMBAY HC REMANDS AUDI'S 'Q6' TRADEMARK APPLICATION The Bombay HC has remanded Audi's trademark application for 'Q6' back to the senior examiner of trademark for reconsideration. The senior examiner [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The complete document can be viewed at this link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The complete document can be viewed at this link: [...]

Mumbai: Appointment of Mr. Madhava Rao Karicherla as Associate Vice President - Formulation Research and Development, Pharma Division, Kothur Unit of the Company w.e.f., 15th November, 2024 The complete document [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of The Board Meeting The complete document can be viewed at this link: [...]

Mumbai: Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarte ended 30th September, 2024 The complete document can be viewed at this link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report The complete document can be viewed at this link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Reg. 34 (1) Annual Report. The complete document can be viewed at this link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - 41St Annual General Meeting The complete document can be viewed at this link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The complete document can be viewed at this link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The complete document can be viewed at this link: [...]

Mumbai: BSE (Bombay Stock Exchange) has issued the following notice: The Exchange, in order to verify certain news articles appearing in the various newspapers/ websites/ television channels and also to [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The complete document can be viewed at this link: [...]

New Delhi: High Court of Delhi has issued the following order: [...]

PARSIPPANY: Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially [...]

-- Based in New Jersey, Natco Pharma USA is the U.S. Sales and Marketing company for all DASH products, as well as current, future and non-committed products developed and manufactured [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Reg. 34 (1) Annual Report. The full document can be viewed at the following link: [...]

Mumbai: 40th Annual General Meeting of the Company to be held on 29th September, 2023 at 10.30 IST The full document can be viewed at the following link: [...]

Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, reported that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The full document can be viewed at the following link: [...]

Mumbai: Compliances - Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ending June 30, 2023 The full document can be viewed at the following link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Related Party Transactions For The Half Year Ended March 31, 2023. The full document can be viewed at the following link: [...]

Mumbai: Annual Secretarial Compliance Report for the year ended 31st March 2023 The full document can be viewed at the following link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The full document can be viewed at the following link: [...]

Contract Award for Supply of 820108360012-tab apixaban 2.5 mg. firms offer : brand as accepted : apigat 2.5 mg. mfgd. & mktd. by m/s. natco pharma ltd.Sanya Enterprises Contractor name [...]

Mumbai: Compliance Certificate for the period ended 31st March 2023 The full document can be viewed at the following link: [...]

Mumbai: Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended 31st March 2023 The full document can be viewed at the following link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Closure of Trading Window The full document can be viewed at the following link: [...]

Mumbai: Intimation of Loss of share Certificate The full document can be viewed at the following link: [...]

Mumbai: intimation for issue of duplicate share certificate The full document can be viewed at the following link: [...]

PARSIPPANY: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths [...]

ENPNewswire-March 10, 2023--Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid, in the U.S (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 09032023 - PARSIPPANY - Teva [...]

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, and NATCO Pharma Limited, announced on 9 Mar 2023 the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States. The companies have launched four other strengths of the product in Mar 2022 in the US market. With the launch the companies made available all the strengths of lenalidomide in the US market. Teva's lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment. With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the US. Revlimid had sales of $2.9 bn/y as of Jan 2023, according to IQVIA data. Original source: Teva Pharmaceuticals Industries, website: http://www.tevapharm.com, Copyright Teva Pharmaceuticals Industries Ltd 2023., joint venture; sales; dexamethasone; generic pharmaceuticals; lenalidomide; lenalidomide; NATCO Pharma; Teva Pharmaceutical Industries; Teva [...]

PARSIPPANY, N.J. & TEL AVIV, Israel & HYDERABAD, India -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; [...]

Mumbai: NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/03/2023 ,inter alia, to consider and approve proposal for buyback [...]

Dublin: Research and Markets has issued the following news release: The 'Global Diabetes Care Drugs Market - Forecasts from 2022 to 2027' report has been added to ResearchAndMarkets.com's offering. The [...]

SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ('Zhongchao' or the 'Company'), a platform-based internet technology company offering services to patients with oncology and other major diseases, today [...]

Mumbai: Compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 2022 The full document can be viewed at the following link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The full document can be viewed at the following link: [...]

Mumbai: NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate The full document can be viewed at the following link: [...]